Announced details
Treatment of mature B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and B-cell non-Hodgkin lymphoma (B-cell NHL)
Overall response rate of 73% in the 400 mg BID CLL/SLL cohort; overall response rate of 86% in patients previously treated with both a covalent BTK inhibitor and a BCL-2 inhibitor; overall response rate of 75% in patients with BTK mutations; overall response rate of 100% in patients with MCL; overall and major response rates of 100% in patients with WM; 10% incidence of grade 3 or higher study treatment-related adverse events; 2% study discontinuation rate
As of the data cutoff date (8 May 2026), 58 patients had enrolled across 5 dose cohorts (33 with CLL, 9 with MCL, 4 with WM, 6 with MZL and 6 with FL)
Our company is conducting the clinical trial, and Nitin Jain, MD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, gave the poster presentation. Details of the capital, personnel and business relationships are Not disclosed.
Nitin Jain, MD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, gave the poster presentation. Other information, including location, representative, capital, year established and business activities, is Not disclosed.
NCT05602363 (clinical trial identification number); expiration date is Not disclosed
United States (location of the Phase 1b trial)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Poster presented at the European Hematology Association (EHA) 2026 Congress; data cutoff date: 8 May 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | docirbrutinib, AS-1763 |
| Counterparty | The University of Texas MD Anderson Cancer Center (presenter's affiliation) |
| Counterparty overview | Nitin Jain, MD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, gave the poster presentation. Other information, including location, representative, capital, year established and business activities, is Not disclosed. |
| Relationship with the Company | Our company is conducting the clinical trial, and Nitin Jain, MD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, gave the poster presentation. Details of the capital, personnel and business relationships are Not disclosed. |
| Launch date | Dosing in the dose-expansion portion began in October 2024 (actual) |
| Applicable area | Treatment of mature B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and B-cell non-Hodgkin lymphoma (B-cell NHL) |
| Registration number and expiry date | NCT05602363 (clinical trial identification number); expiration date is Not disclosed |
| Location | United States (location of the Phase 1b trial) |
| Quantitative Effects | Overall response rate of 73% in the 400 mg BID CLL/SLL cohort; overall response rate of 86% in patients previously treated with both a covalent BTK inhibitor and a BCL-2 inhibitor; overall response rate of 75% in patients with BTK mutations; overall response rate of 100% in patients with MCL; overall and major response rates of 100% in patients with WM; 10% incidence of grade 3 or higher study treatment-related adverse events; 2% study discontinuation rate |
| Usage history | As of the data cutoff date (8 May 2026), 58 patients had enrolled across 5 dose cohorts (33 with CLL, 9 with MCL, 4 with WM, 6 with MZL and 6 with FL) |
| Source | Poster presented at the European Hematology Association (EHA) 2026 Congress; data cutoff date: 8 May 2026 |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The latest data from the ongoing Phase 1b trial of docirbrutinib were presented at EHA 2026. The latest results were described as supporting the continuation of docirbrutinib's clinical development into the next stage of clinical trials.